P. Lechat Et Al. , "Within-subject pharmacokinetic variability has a strong influence on individual exposure ratios in bioequivalence studies, hence on drug formulation interchangeability," European Journal of Clinical Pharmacology , vol.79, no.11, pp.1565-1578, 2023
Lechat, P. Et Al. 2023. Within-subject pharmacokinetic variability has a strong influence on individual exposure ratios in bioequivalence studies, hence on drug formulation interchangeability. European Journal of Clinical Pharmacology , vol.79, no.11 , 1565-1578.
Lechat, P., KIR, F., Marquet, P., & Woillard, J., (2023). Within-subject pharmacokinetic variability has a strong influence on individual exposure ratios in bioequivalence studies, hence on drug formulation interchangeability. European Journal of Clinical Pharmacology , vol.79, no.11, 1565-1578.
Lechat, Philippe Et Al. "Within-subject pharmacokinetic variability has a strong influence on individual exposure ratios in bioequivalence studies, hence on drug formulation interchangeability," European Journal of Clinical Pharmacology , vol.79, no.11, 1565-1578, 2023
Lechat, Philippe Et Al. "Within-subject pharmacokinetic variability has a strong influence on individual exposure ratios in bioequivalence studies, hence on drug formulation interchangeability." European Journal of Clinical Pharmacology , vol.79, no.11, pp.1565-1578, 2023
Lechat, P. Et Al. (2023) . "Within-subject pharmacokinetic variability has a strong influence on individual exposure ratios in bioequivalence studies, hence on drug formulation interchangeability." European Journal of Clinical Pharmacology , vol.79, no.11, pp.1565-1578.
@article{article, author={Philippe Lechat Et Al. }, title={Within-subject pharmacokinetic variability has a strong influence on individual exposure ratios in bioequivalence studies, hence on drug formulation interchangeability}, journal={European Journal of Clinical Pharmacology}, year=2023, pages={1565-1578} }